Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

How a Ketogenic Diet Affects Hormones and Metabolism in Women (SHEKAN)

12. listopadu 2026 aktualizováno: Madison Kackley, Ohio State University

Strategic Hormonal Evaluation in Keto-Adaptation

This study is looking at how a ketogenic diet (a way of eating that is high in fat and very low in carbohydrates) affects hormones, metabolism, and body composition in healthy women who have regular menstrual cycles. While ketogenic diets have become popular and have been studied in men and in people with certain health conditions, much less is known about how this way of eating affects the hormones and cycles of healthy, premenopausal women.

Researchers believe that a ketogenic diet may cause measurable changes in reproductive hormones (such as estrogen and progesterone), metabolic markers (like ketone and cholesterol levels), and body composition (such as body fat and lean muscle mass) across the menstrual cycle. The study will also explore whether the diet affects mood, sleep, and overall well-being.

Participants will follow a ketogenic diet for 12 weeks, roughly covering three menstrual cycles. During the first month, they will receive help with meal planning and food, and for the remaining weeks they will follow the diet on their own with continued support from a dietitian. Throughout the study, participants will check in weekly for blood draws, body composition scans, and a resting metabolism test, and will use at-home tools such as a smart ring and daily finger-stick tests to track their ketone levels and hormone patterns. Participants will also complete surveys about their mood, sleep, and general well-being.

By studying these changes closely, the research team hopes to better understand how a ketogenic diet affects women's health and hormones, which could help guide future dietary recommendations designed specifically for women.

Přehled studie

Postavení

Nábor

Podmínky

Intervence / Léčba

Detailní popis

etogenic diets induce a metabolic shift from glucose to fat as the primary energy substrate, resulting in nutritional ketosis and associated changes in insulin sensitivity, lipid profiles, and body composition. While ketogenic diets have been studied extensively in the context of epilepsy, obesity, type 2 diabetes, and neurodegenerative disease, most existing research either underrepresents women or fails to account for hormonal fluctuations across the menstrual cycle. Preliminary evidence suggests that sex hormones and substrate metabolism differ meaningfully between men and women in their response to dietary interventions, yet these differences remain poorly characterized during ketogenic adaptation, particularly in healthy, regularly menstruating women.

This pilot study is designed to characterize the physiological, hormonal, metabolic, and behavioral adaptations that occur during a 12-week, well-formulated ketogenic diet in healthy, premenopausal women, capturing data across approximately three consecutive menstrual cycles. The diet is structured in two phases: an initial 4-week period with controlled feeding support (grocery provision or meal delivery services matched to individual caloric needs), followed by 8 weeks of self-guided dietary adherence supported by ongoing dietitian consultation and educational materials. Dietary adherence and ketosis status (target: ≥0.5 mmol/L blood BHB) are monitored daily via at-home fingerstick testing.

Participants attend weekly in-person study visits for the duration of the 12-week intervention, during which fasting venous blood is drawn to assess reproductive hormone levels, resting metabolic rate is measured via indirect calorimetry, and body composition is tracked using bioelectrical impedance (InBody). Full-body DXA scans, which provide a more precise measure of fat mass, lean mass, and visceral adiposity, are performed only at baseline and at the final Week 16 visit, in order to limit participants' cumulative radiation exposure. Menstrual cycle phase and ovulatory status are tracked continuously using a wearable basal body temperature ring and urine-based hormone test strips, allowing the research team to align hormonal blood draws with specific points in each participant's cycle. Validated PROMIS instruments are used to assess mood, sleep quality, anxiety, depression, and cognitive function at scheduled intervals throughout the study.

As a pilot study, SHEKAN is designed primarily to assess feasibility and estimate effect sizes to inform the design of future, larger-scale investigations, rather than to test a specific hypothesis with adequate statistical power to detect small between-group differences. Findings are intended to help characterize sex-specific responses to ketogenic diets and inform future research and clinical guidance regarding women's metabolic and reproductive health during dietary intervention.

Typ studie

Intervenční

Zápis (Odhadovaný)

40

Fáze

  • Nelze použít

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

    • Ohio
      • Columbus, Ohio, Spojené státy, 43210
        • Nábor
        • Physical Activity and Educational Services Building
        • Kontakt:
          • Program Manager Department of Human Sciences - Kinesiology
          • Telefonní číslo: 6142470287
          • E-mail: roe.236@osu.edu
        • Vrchní vyšetřovatel:
          • Madison Kackley, PhD, Kinesiology

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let až 40 let (Dospělý)

Přijímá zdravé dobrovolníky

Ano

Pohlaví způsobilá ke studiu

Ženský

Popis

Inclusion Criteria:

  • Healthy Women aged 18-40
  • Self-reported, 27-32 day menstrual cycles
  • Must have access to a smartphone, tablet or computer to access the diet survey and resources
  • Must be willing to self-report menstrual cycles

Exclusion Criteria:

  • History of reproductive disorders
  • Pregnancy or lactation during the study period
  • Recurring disordered eating behaviors or other food security concerns
  • Suffered a lower body injury in the last 6 months
  • Other major health concerns

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Základní věda
  • Přidělení: N/A
  • Intervenční model: Přiřazení jedné skupiny
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Ketogenic Diet Intervention Group

Healthy, premenopausal women (ages 18-40) with regular menstrual cycles will follow a 12-week well-formulated ketogenic diet designed to maintain nutritional ketosis (≥0.5 mmol/L BHB). During the first 4 weeks, participants receive controlled feeding support (grocery provision or meal delivery services). Weeks 5-12 transition to a self-guided ketogenic diet with continued dietitian support and educational resources. Participants undergo weekly in-person study visits (blood draws, resting metabolic rate testing, body composition scans, and validated surveys) plus daily at-home monitoring (fingerstick ketone/glucose testing, nightly wearable ring, and urine ovulation tracking) across approximately 16 weeks total, including baseline and final follow-up visits.

A high-fat, low-carbohydrate, moderate-protein diet intended to induce and maintain nutritional ketosis over 12 weeks, with an initial 4-week period of controlled feeding support followed by 8 weeks of self-guided adherence with dietitian consultation and educational materials.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Change in Ovulatory Status
Časové okno: Baseline to 12 weeks

To evaluate whether ketogenic dietary intervention or exogenous ketone supplementation restores ovulatory function in women with Polycystic Ovary Syndrome (PCOS). Ovulatory status will be assessed using a combination of validated measures, including basal body temperature monitoring via BBT, urinary luteinizing hormone (LH) surge detection using ovulation predictor kits, and serum progesterone levels. Participants will be classified as ovulatory or anovulatory based on hormonal and temperature cycle confirmation.

Baseline to 12 weeks

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Change in Serum Progesterone Concentration (ng/mL)
Časové okno: Baseline to 12 weeks

To determine the effects of ketogenic diet and exogenous ketone supplementation on circulating reproductive hormone concentrations. Serum progesterone will be analyzed using standard immunoassay techniques (Quest Diagnostics panels and/or validated ELISA assays). Hormonal changes will be compared between baseline and post-intervention to assess improvements in reproductive axis regulation.

Baseline to 12 weeks
Change in Serum Estradiol Concentration (pg/mL)
Časové okno: Baseline to 12 weeks

To determine the effects of ketogenic diet and exogenous ketone supplementation on circulating reproductive hormone concentrations. Serum estradiol will be analyzed using commercially available immunoassay kits (Quest Diagnostics panels and/or validated ELISA assays). Hormonal changes will be compared between baseline and post-intervention to assess improvements in reproductive axis regulation.

Baseline to 12 weeks
Change in Serum Luteinizing Hormone Concentration (mIU/mL)
Časové okno: Baseline to 12 weeks

To determine the effects of ketogenic diet and exogenous ketone supplementation on circulating reproductive hormone concentrations. Serum luteinizing hormone (LH) will be analyzed using standard immunoassay techniques (Quest Diagnostics panels and/or validated ELISA assays). Hormonal changes will be compared between baseline and post-intervention to assess improvements in reproductive axis regulation.

Baseline to 12 weeks
Change in Serum Follicle Stimulating Hormone Concentrations (mIU/mL)
Časové okno: Baseline to 12 weeks

To determine the effects of ketogenic diet and exogenous ketone supplementation on circulating reproductive hormone concentrations. Serum follicle-stimulating hormone (FSH) will be analyzed using standard immunoassay techniques (Quest Diagnostics panels and/or validated ELISA assays). Hormonal changes will be compared between baseline and post-intervention to assess improvements in reproductive axis regulation.

Baseline to 12 weeks
Change in Daily Fasting BHB (mmol/L)
Časové okno: Baseline to 12 weeks (Daily)

To assess changes in metabolic parameters including fasting β-hydroxybutyrate (BHB). Capillary ketones will be measured daily using KetoMojo handheld monitors.

Baseline to 12 weeks (Daily)
Change in Daily Fasting Glucose (mg/dL)
Časové okno: Baseline to 12 weeks (Daily)

To assess changes in metabolic parameters including fasting glucose. Capillary glucose will be measured daily using KetoMojo handheld monitors.

Baseline to 12 weeks (Daily)
Change in Serum Insulin Concentration (µIU/mL)
Časové okno: Baseline to 12 weeks

To assess the effect of ketogenic diet and exogenous ketone supplementation on fasting insulin levels. Serum insulin will be measured at laboratory visits via immunoassay (Quest Diagnostics or validated ELISA). Mean change from baseline will be compared across groups.

Baseline to 12 weeks
Change in Serum Total Cholesterol Concentration (mg/dL)
Časové okno: Baseline to 12 weeks

To assess changes in fasting serum total cholesterol in response to ketogenic diet and exogenous ketone supplementation. Blood samples will be collected biweekly and analyzed using standard clinical chemistry methods (Quest Diagnostics). Mean change from baseline to 12 weeks will be reported.

Baseline to 12 weeks
Change in Serum Triglyceride Concentration (mg/dL)
Časové okno: Baseline to 12 weeks

To determine the effect of ketogenic diet and exogenous ketone supplementation on fasting triglyceride concentrations. Serum triglycerides will be measured via standard lipid panel. Mean change from baseline to 12 weeks will be compared across groups.

Baseline to 12 weeks
Change in Serum LDL Cholesterol Concentration (mg/dL)
Časové okno: Baseline to 12 weeks

To assess the effect of ketogenic diet and exogenous ketone supplementation on fasting low-density lipoprotein (LDL) cholesterol. Serum LDL will be measured via standard lipid panel (Quest Diagnostics). Mean change from baseline to post-intervention will be reported.

Baseline to 12 weeks
Change in Serum HDL Cholesterol Concentration (mg/dL)
Časové okno: Baseline to 12 weeks

To evaluate changes in fasting high-density lipoprotein (HDL) cholesterol following ketogenic diet or exogenous ketone supplementation. Serum HDL will be analyzed by clinical chemistry methods. Mean change from baseline to 12 weeks will be reported.

Baseline to 12 weeks

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Obecné publikace

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

6. února 2026

Primární dokončení (Odhadovaný)

1. srpna 2028

Dokončení studie (Odhadovaný)

1. prosince 2028

Termíny zápisu do studia

První předloženo

2. listopadu 2026

První předloženo, které splnilo kritéria kontroly kvality

12. listopadu 2026

První zveřejněno (Aktuální)

18. listopadu 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

18. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

12. listopadu 2026

Naposledy ověřeno

1. listopadu 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • STUDY20250337

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

ANO

Popis plánu IPD

Deidentified datasets (no direct identifiers; no genetic/genomic data, as none will be generated for this study)

Typ podpůrných informací pro sdílení IPD

  • PROTOKOL STUDY
  • MÍZA

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .